Neighborhood characteristics and the spatial concentration of crime: Evidence for Bogotá

Using a unique neighborhood crime dataset for Bogotá in 2011, this study uses a spatial econometric approach and examines the role of socioeconomic and agglomeration variables in explaining the variance of crime. It uses two different types of crime, violent crime represented in homicides and property crime represented in residential burglaries. These two types of crime are then measured in non-standard crime statistics that are created as the area incidence for each crime in the neighborhood. The existence of crime hotspots in Bogotá has been shown in most of the literature, and using these non-standard crime statistics at this neighborhood level some hotspots arise again, thus validating the use of a spatial approach for these new crime statistics. The final specification includes socioeconomic, agglomeration, land-use and visual aspect variables that are then included in a SARAR model an estimated by the procedure devised by Kelejian and Prucha (2009). The resulting coefficients and marginal effects show the relevance of these crime hotspots which is similar with most previous studies. However, socioeconomic variables are significant and show the importance of age, and education. Agglomeration variables are significant and thus more densely populated areas are correlated with more crime. Interestingly, both types of crimes do not have the same significant covariates. Education and young male population have a different sign for homicide and residential burglaries. Inequality matters for homicides while higher real estate valuation matters for residential burglaries. Finally, density impacts positively both crimes.

Clinical experience of clobazam as add-on treatment in a cohort of adults with epilepsy

Objective: Epilepsy is a common neurologic disorder affecting 1% of the world population with one-third of these patients failing to have seizure control for more than one year. Clobazam is a long-acting benzodiazepine used worldwide for the treatment of epilepsy. This antiepileptic drug has demonstrated great clinical benefits with mild side effects. The objective of this study was to better understand the efficacy of clobazam treatment on adult patients with refractory epilepsy. Design: A retrospective review of 44 adult patients with diagnosis of epilepsy that were seen at our Epilepsy Clinic between January 2014 and May 2015. Setting: An outpatient epilepsy clinic at the Hospital Universitario Fundación Santa Fe de Bogota, Colombia. Participants: 44 adult patients with diagnosis of epilepsy. Measurements: Seizure frequency, adverse effects and the use of concomitant AEDs were reviewed in each of the patient´s clinical charts. Results: The responder rate of patients with clobazam was 52% at 3 months, 50% at 6 months and 55% at 12 month. Seizure freedom rates at 3, 6 and 12 months were 18%, 25% and 25% respectively. Clobazam related adverse events occurred only in four patients (9%) at the end of the twelve months with somnolence being the most common. Conclusion: These findings suggest that clobazam treatment in adult patients with focal or generalized epilepsy is effective and safe. Its use should be considered early when first-line agents fail to provide seizure control.